You are here
P&T September 2013
As genotyping and genetic testing become more sophisticated, accessible, and costeffective, these tools hold great promise for predicting and improving responses to medications.
FDA approvals, drug indications, and updates
Afatinib (Gilotrif) for non–small-cell lung cancer; golimumab (Simponi Aria) for moderate-to-severe active rheumatoid arthritis; and levomilnacipran (Fetzima) extended release for major depressive disorder